Strides receives USFDA approval for Levetiracetam Oral Solution
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Granules now has a total of 58 ANDA approvals from US FDA
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Peacock also serves as a Director and Chair of the Audit and Finance Committee of UCB SA, a biopharmaceutical company focusing on neurology and immunology
According to IQVIA sales data for the period ending January 2022, Vimpat tablets market achieved annual sales of approx. US $ 1.7 billion
The company plans to launch the product immediately
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
Subscribe To Our Newsletter & Stay Updated